Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.11.22.566980

AP-1 regulates heterogeneous cellular dormancy in TNBC

Dong, Y.·Bai, J.·Fu, R.·Su, H.·Wu, S.·Tang, D. G.·Zhou, J.
View original source ↗Export metadata ↓

Abstract

BackgroundDormant or slow cycling cells (SSCs) pre-exist in tumor and responsible for chemo-resistant and tumor recurrence. Due to their low differentiation and dormancy characteristics, SCCs are resistant to standard chemotherapy and targeted therapy. Label-retaining is a common method used to identify and isolate live SCCs. However, it remains unclear whether different label-retaining methods yield distinct SCC subpopulations. In this study, we investigated that various label-retaining methods result in overlapping yet heterogeneous subpopulations of SCCs. Additionally, we explored the molecular mechanisms regulating dormancy in triple-negative breast cancer (TNBC). MethodsWe employed multiple label-retaining methods to simultaneously label MDA-MB-231 cells, thereby generating distinct subpopulations of SCCs. We subsequently analyzed these subpopulations for heterogeneity in cell cycle distribution, drug resistance, invasive capacity, and other characteristics using real-time PCR, flow cytometry, and Transwell assays. RNA-seq analysis was performed to characterize the gene expression profiles of the SCCs. Furthermore, we used real-time PCR, Western blotting, immunofluorescence, and luciferase assays to investigate the role of characteristic AP-1 expression in dormancy regulation. Finally, the therapeutic effects of targeting AP-1 in the treatment of TNBC were assessed using a cell-derived xenograft model. ResultsWe labeled and separated three overlapping but non-identical SCCs subpopulations. We found that all three SCCs subgroups are cell cycle arrested. Additionally, Violet enriched SCCs showed stronger drug resistance and more G1 phase arrest, while Claret enriched SCCs demonstrated enhanced migratory and invasive abilities, along with more G2/M phase arrest. Furthermore, we observed upregulation of AP-1 expression in SCCs, and the JunB subunit of AP-1 promoted the expression of CDKN1A and GADD45A, thereby maintaining cell cycle arrest. CC-930 can inhibit AP-1 transcriptional activity by suppressing JNK activity, ultimately improving the therapeutic efficacy and prognosis of TNBC when used in combination with chemotherapy drugs. ConclusionsWe obtained three subpopulations of SCCs with heterogeneous drug resistance. Our findings suggest that AP-1 plays a regulatory role in dormancy regulation in TNBC, and elucidated the molecular function of JunB subunit. Targeting AP-1 with CC-930 has the potential to improve the treatment and prognosis of TNBC. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/566980v2_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@129ce76org.highwire.dtl.DTLVardef@1b1cfa1org.highwire.dtl.DTLVardef@b68315org.highwire.dtl.DTLVardef@57faf1_HPS_FORMAT_FIGEXP M_FIG C_FIG TNBC harbors both fast-cycling cells (FCCs) and functionally overlapping slow-cycling cell (SCC) subpopulations that manifest differential drug sensitivities and motility (A) but are commonly regulated by the JunB-containing AP1 complex (B). (A). Slow-cycling (quiescent) TNBC cells in culture (a) identified by different label-retaining approaches phenotypically overlap (b), display differential drug sensitivities (c, d) and motility (e) but share common gene expression profiles (f). (B). Schematic depicting regulation of proliferation in FCCs by the c-Jun/c-Fos AP1 complex (left) and regulation of cellular dormancy in SCCs by c-Jun/JunB AP1 complex.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dong, Y., Bai, J., Fu, R., Su, H., Wu, S., Tang, D. G., Zhou, J.. 2023-11-23. AP-1 regulates heterogeneous cellular dormancy in TNBC. https://doi.org/10.1101/2023.11.22.566980

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology↗
bioRxiv2026

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology↗
bioRxiv2026

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology↗